HISTORICAL FACTS: Enovis | History Defined

Spend $75 or Less to Make Contrarian Bets on These 3 Hard-Hit Value Stocks

The new 52-week highs on the NYSE exceeded the lows by 2.4 times yesterday, while the Nasdaq’s new highs were 2.9 times the lows. Value investors should check out these three new lows.

Barchart · Jun 3

13 Top Stocks With Huge Upside Potential To Buy Now

Top stock picks for long-term growth in 2025 focus on tech, energy, biotech and retail leaders with strong analyst buy ratings and high upside potential.

GOBankingRates · Oct 13, 2025

Enovis Hits Another 52-Week Low. Here’s Why It’s a Contrarian Buy.

The orthopedic medical device company hit its 41st 52-week low. The stock looks unnecessarily beaten down, off 41% over the past 12 months and 62% from its all-time high in November 2021, making it a contrarian buy.

Barchart · Mar 5, 2025

Benzinga's Top Ratings Upgrades, Downgrades For June 16, 2022

Upgrades

Benzinga · Jun 16, 2022

Recap: Enovis Q1 Earnings

  Enovis (NYSE:ENOV) reported its Q1 earnings results on Tuesday, May 10, 2022 at 06:00 AM. Here's what investors need to know about the announcement. Earnings Enovis beat estimated earnings by 5.71%, reporting an EPS of $0.37 versus an estimate of $0.35.

Benzinga · May 10, 2022